PTU - Polskie Towarzystwo Urologiczne
list of articles:

Evaluation of influence of adjuvant and neoadjuvant chemotherapy applied accordin to modified scheme MVAC on survival of patients treated for invasive bladder cancer depending on grading (G) of the tumor
Article published in Urologia Polska 2002/55/1.

authors

Wojciech Kołaczyk 1, Janusz Dembowski 2, Jerzy Lorenz 2, Krzysztof Dudek 3
1 Oddział Urologii Szpitala Wojewódzkiego w Legnicy
Ordynator oddziału: dr Wojciech Kołaczyk
2 Katedra i Klinika Urologii Akademii Medycznej we Wrocławiu
Kierownik kliniki: prof, dr hab. Jerzy Lorenz
3 Zakład Inżynierii Niezawodności i Diagnostyki Politechniki we Wrocławiu

keywords

bladder, invasive bladder cancer, systemic chemotherapy

summary

Assumption. The aim of the paper was to evaluate the influence of systemic chemotherapy applied to modified scheme MVAC in pre- and postoperative form on survival of patients treated for invasive bladder cancer, depending on grading (G) of the tumor. Materials nad methods. Retrospective evaluation of survival was made in three groups of patients: the first included patients who received systemic chemotherapy befor cystectomy (group N), the second were patients who received chemotherapy after operation (group A). The third were patients who received only cystectomy (group K). Moreover, the patients were divided into two subgroups: the first were patients whose tumor was confined to bladder (Tl+T2+T3a), the second included patients whose tumor expanded beyond the bladder (T3b+T4a+T4b). In patients the tumor was composed of transitional epithelium of urinary tract. The evaluation concerned patients with tumor in stage G2 or G3. Chemotherapy was applied in doses like in original scheme MVAC, excluding MTX and VBL in 15ln and 22ncl day of the cycle. Statistical calculations were made using life duration tables.
Results. In the group of patients where the tumor was confined to bladder and was in grode G2 and G3, from eight years of followup, survival was higher in patients subjected to preoperative chemoterapy.
Conclusion. The survival of patients with tumor G2 or G3 was higher in group with neoadjuvant chemotherapy; systemic chemotherapy has bigger influence on survival patients with bad differentation tumor.

references

  1. 1. Srougi M, Simon AW: Primary methotrexate, vinblaslin, doxoru-bicin and cisplalin chemotherapy and bladder preservation in locally invasive bladder cancer: 5 year followup. J Urol 1994; 593-597.
  2. 2. Rueben H, Olio T: Lokal foigeschrittenes oder metastasiertes Hamblasenkarzinom. Urologie 2001; 40; 464-467.
  3. 3. International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Part)\\\' EORTC Genilo-Urinary Group, Australian Bladder Cancer Siudy Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tralamienlo Oncologi-co: Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. The Lancet 1999; 354,14; 533-540.
  4. 4. Skinner DG, Daniels, JR Christy AR, Licskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145; 459-467.
  5. 5. Malmstroem P, Rintala E, Wahlquist R, Hellstroem P, Hellsten S, Hannisdal E and Members of the Nordic Cooperative Bladder Cancer Study Group: Five year followup of a prospective trial of radical cystectomy and neodajuvant chemotherapy: Nordic Cystectomy Trial I. J Urol 1996; 155; 1903-1906.
  6. 6. Seretta V, Lo Greco G, Pavonc C, Pavone-Macaluso M: The fate of patients with locally advanced bladder cancer treated consen\\\'atively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience. J Urol 1998: 159; 1187-1191.
  7. 7. Sternberg CN, MD, Arena MG, Calabresi MDF, MD, De Car-li P, MD, Plalania A, MD, Zeuli M, MD, Giannarelli M, MS, Cancrini A, MD, Pansadoro V, M. D: Neoadjuvant M. -VAC (ethotrexate, vinblastine, doxorubicin, and cisplatin) for infńtra-ting transitional cell carcinoma of the bladder. Cancer 1993; 72,6; 1975-1982.
  8. 8. Herr HW, Bajorin DF, Scher HI: Neoadjuvant chemotherapy and bladder sparing suigeiy for invasive bladder cancer: ten-year outcame. J Clin Oncol 1998; 16, 4; 1298-1301.
  9. 9. Dimopoulos MA, Moulopoulos LA; Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol 1998; 16, 4; 1601-1612.
  10. 10. Martinez-Pineiro JA, Martinez-Pineiro L: The role of neoadjuvant chemotherapy for invasive bladder cancer. Brit J Urol 1998; 82; 33-42.
  11. 11. Schulz-Lampel D, Lampel A: Neoadjuvant and adjuvant treatment of locally invasivae bladder cancer. Cur Op in Urol 1999; 8; 419-424.

correspondence

Wojciech Kolaczyk
Szpital Wojewódzki Oddział Urologii
al. Iwaszkiewicza 5
76-866 Legnica